

AETNA INC /PA/  
Form 424B5  
August 25, 2010

**Table of Contents**

**Filed Pursuant to Rule 424(b)(5)**  
**Registration File No.: 333-155961**

**CALCULATION OF REGISTRATION FEE**

<b>Title of Each Class of Securities to be Registered</b>	<b>Amount to be Registered</b>	<b>Aggregate Offering Price</b>	<b>Registration Fee(1)</b>
3.95% Senior Notes due 2020	\$750,000,000	98.859%	\$53,475

(1) Calculated in accordance with Rule 457(r) under the Securities Act of 1933.

**PROSPECTUS SUPPLEMENT****August 24, 2010****(To Prospectus Dated December 5, 2008)****AETNA INC.****\$750,000,000 3.95% Senior Notes Due 2020**

We are offering \$750,000,000 of our 3.95% senior notes due 2020 (the Notes).

The Notes will bear interest at a rate of 3.95% per year. Interest on the Notes is payable on March 1 and September 1 of each year, beginning March 1, 2011. The Notes will mature on September 1, 2020. We may redeem the Notes at any time, in whole or in part, at the redemption prices described in this prospectus supplement.

The Notes will be unsecured senior obligations of our company and will rank equally with all of our other existing and future unsecured senior indebtedness.

**Investing in the Notes involves risks. See Forward-Looking Information/Risk Factors in our 2009 Aetna Annual Report, Financial Report to Shareholders incorporated by reference into our Annual Report on Form 10-K for the year ended December 31, 2009, and Forward-Looking Information/Risk Factors in our Quarterly Reports on Form 10-Q for the quarters ending March 31, 2010 and June 30, 2010.**

**Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the related prospectus is truthful or complete. Any representation to the contrary is a criminal offense.**

	<b>Per Note</b>	<b>Total</b>
Public Offering Price(1)	98.859%	\$ 741,442,500
Underwriting Discount	0.650%	\$ 4,875,000
Proceeds to Aetna Inc. (before expenses)	98.209%	\$ 736,567,500

(1) Plus accrued interest, if any, from August 27, 2010, if settlement occurs after that date.

The underwriters expect to deliver the Notes in registered book-entry form only through the facilities of The Depository Trust Company and its direct and indirect participants, including Euroclear and Clearstream, Luxembourg to purchasers on or about August 27, 2010.

*Joint Book-Running Managers*

**Barclays Capital**

**RBS**

**UBS Investment Bank**

*Senior Co-Managers*

**BofA Merrill Lynch  
Goldman, Sachs & Co.  
US Bancorp**

**Citi  
J.P. Morgan**

**Credit Suisse  
Morgan Stanley  
Wells Fargo Securities**

*Co-Managers*

**BNY Mellon Capital Markets, LLC  
Mitsubishi UFJ Securities**

**PNC Capital Markets LLC**

**Fifth Third Securities, Inc.  
SunTrust Robinson Humphrey**

---

You should rely only on the information contained in or incorporated by reference in this prospectus supplement and the accompanying prospectus and in any free writing prospectus filed by the Company with the Securities and Exchange Commission. If information in this prospectus supplement is inconsistent with the accompanying prospectus, you should rely on the prospectus supplement. We and the underwriters have not authorized anyone to provide you with information that is different. This prospectus supplement and the accompanying prospectus may only be used where it is legal to sell these securities. The information in this prospectus supplement and the accompanying prospectus may only be accurate as of the date of this prospectus supplement, the accompanying prospectus or the information incorporated by reference herein or therein, and the information in any free writing prospectus may only be accurate as of the date of such free writing prospectus. Our business, financial condition, results of operations and/or prospects may have changed since those dates.

## TABLE OF CONTENTS

	<u>Page</u>
<b>PROSPECTUS SUPPLEMENT</b>	
<u>THE OFFERING</u>	S-2
<u>THE COMPANY</u>	S-4
<u>WHERE YOU CAN FIND MORE INFORMATION</u>	S-4
<u>CAPITALIZATION</u>	S-5
<u>USE OF PROCEEDS</u>	S-6
<u>SELECTED FINANCIAL INFORMATION</u>	S-7
<u>DESCRIPTION OF THE NOTES</u>	S-8
<u>UNDERWRITING</u>	S-14
<u>VALIDITY OF THE NOTES</u>	S-17
<u>ERISA MATTERS</u>	S-17
<b>PROSPECTUS</b>	
<u>THE COMPANY</u>	1
<u>WHERE YOU CAN FIND MORE INFORMATION</u>	1
<u>SPECIAL NOTE ON FORWARD-LOOKING STATEMENTS AND RISK FACTORS</u>	2
<u>USE OF PROCEEDS</u>	2
<u>DESCRIPTION OF CAPITAL STOCK</u>	2
<u>DESCRIPTION OF DEBT SECURITIES</u>	8
<u>FORM OF DEBT SECURITIES</u>	14
<u>CERTAIN UNITED STATES FEDERAL TAX CONSEQUENCES</u>	16
<u>VALIDITY OF SECURITIES</u>	21
<u>INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</u>	21
<u>ERISA MATTERS</u>	22

In this prospectus supplement and the accompanying prospectus, all references to Aetna, the Company, we, us and refer to Aetna Inc. and its consolidated subsidiaries, unless the context otherwise requires. The underwriters refers to the financial institutions named on the front cover of this prospectus supplement.

We are offering the Notes globally for sale in those jurisdictions in the United States, Europe, Asia and elsewhere where it is lawful to make such offers. The distribution of this prospectus supplement and the accompanying prospectus and the offering of the Notes in certain jurisdictions may be restricted by law. Persons who receive this prospectus supplement and the accompanying prospectus should inform themselves about and observe any such

restrictions. This prospectus supplement and the accompanying prospectus do not constitute, and may not be used in connection with, an offer or solicitation by anyone in any jurisdiction in which such offer or solicitation is not authorized or in which the person making such offer or solicitation is not qualified to do so or to any person to whom it is unlawful to make such offer or solicitation. See Underwriting.

S-1

---

**Table of Contents**

**THE OFFERING**

The offering terms of the Notes are summarized below solely for your convenience. This summary is not a complete description of the Notes. You should read the full text and more specific details contained elsewhere in this prospectus supplement and the accompanying prospectus. For a more detailed description of the Notes, see the discussion under the caption "Description of the Notes" beginning on page S-8 of this prospectus supplement.

Issuer	Aetna Inc.
Notes Offered	\$750,000,000 aggregate principal amount of 3.95% senior notes due 2020 (the "Notes").
Maturity	The Notes will mature on September 1, 2020.
Interest Payment Dates	March 1 and September 1, beginning March 1, 2011.
Optional Redemption	We may redeem the Notes at any time, in whole or in part, at the redemption prices described in this prospectus supplement. We are not required to establish a sinking fund to retire or repay the Notes.
Repurchase upon Change of Control	Upon the occurrence of both (1) a Change of Control (as defined in "Description of the Notes") and (2) a downgrade of the Notes below an investment grade rating by each of the Rating Agencies (as defined in "Description of the Notes") within a specified period, we will be required to make an offer to purchase all of the Notes at a price equal to 101% of the principal amount of the Notes, plus any accrued and unpaid interest to the date of repurchase. See "Description of the Notes" Repurchase Upon a Change of Control.
Ranking	The Notes will be our senior unsecured and unsubordinated obligations and will rank equally with all of our existing and future senior unsecured indebtedness and senior to all of our subordinated indebtedness. See "Description of the Notes."
Additional Issuances	In the future we may, without the consent of the holders of the Notes, increase the aggregate principal amount of Notes offered on the same terms and conditions (except that the issue price and issue date may vary).
Use of Proceeds	We will use the estimated \$735,767,500 in net proceeds after deducting underwriting discounts and estimated offering expenses from this offering for general corporate purposes, including the repayment of our short-term or long-term debt. See "Use of Proceeds."
Covenants	The indenture for the Notes contains limitations on liens on common stock of our Principal Subsidiaries (as defined in "Description of Debt Securities" in the accompanying prospectus) and limits our ability to consolidate with or merge with or into any other person (other than in a merger or

consolidation in which we are the surviving person) or sell our property or assets as, or substantially as, an entirety to any person. These covenants are subject to important qualifications and limitations. See Description of Debt Securities Limitations on Liens on Common Stock of Principal Subsidiaries and Consolidation, Merger and Sale of Assets in the accompanying prospectus.

S-2

---

**Table of Contents**

Except for the limitation on liens, the indenture for the Notes does not restrict our ability to incur additional indebtedness.

Minimum Denominations

The Notes will be issued and may be transferred only in minimum denominations of \$2,000 and multiples of \$1,000 in excess thereof.

Risk Factors

For a discussion of factors you should carefully consider before deciding to purchase the Notes, see *Forward-Looking Information/ Risk Factors* in our 2009 Aetna Annual Report, Financial Report to Shareholders (the *2009 Annual Report* ), incorporated by reference in, and filed with the Securities and Exchange Commission (the *SEC* ) as an exhibit to, our Annual Report on Form 10-K for the fiscal year ended December 31, 2009, and *Forward-Looking Information/Risk Factors* in our Quarterly Reports on Form 10-Q for the quarters ending March 31, 2010 and June 30, 2010, each as updated in any subsequent filings with the SEC that are incorporated by reference herein.

Address and Phone Number

Our principal executive offices are located at 151 Farmington Avenue, Hartford, Connecticut 06156, and our telephone number is (860) 273-0123.



**Table of Contents**

**THE COMPANY**

We are one of the nation's leading diversified health care benefits companies, serving approximately 35.8 million people at June 30, 2010, with information and resources to help them make better informed decisions about their health care. At June 30, 2010, we served approximately 18.6 million medical members, 13.9 million dental members and 9.7 million pharmacy benefit management services members. We offer a broad range of traditional and consumer-directed health insurance products and related services, including medical, pharmacy, dental, behavioral health, group life and disability plans, medical management capabilities and health care management services for Medicaid plans. We offer these products on both an insured and employer-funded basis. Our customers include employer groups, individuals, college students, part-time and hourly workers, health plans, governmental units, government-sponsored plans, labor groups and expatriates. We also have a large case pensions business that manages a variety of discontinued and other retirement products (including pension and annuity products) primarily for tax qualified pension plans of large customers.

Our principal executive offices are located at 151 Farmington Avenue, Hartford, Connecticut 06156, and our telephone number is (860) 273-0123. Internet users can obtain information about Aetna and its services at <http://www.aetna.com>. This text is not an active link, and our website and the information contained on that site, or connected to that site, are not incorporated into this prospectus supplement.

**WHERE YOU CAN FIND MORE INFORMATION**

We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy any document that we file at the Public Reference Room of the SEC at 100 F Street, N.E., Washington, D.C. 20549. You may obtain information on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. In addition, the SEC maintains an Internet site at <http://www.sec.gov>, from which interested persons can electronically access our filings with the SEC, including the registration statement containing this prospectus supplement (including the exhibits and schedules thereto).

The SEC allows us to incorporate by reference the information we file with them, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important part of this prospectus supplement, and information that we file later with the SEC prior to the termination of the offering under this prospectus supplement will automatically update and supersede this information. We incorporate by reference the documents listed below and all documents we file with the SEC pursuant to Section 13(a), 13(c), 14, or 15(d) of the Securities Exchange Act of 1934, as amended (the Exchange Act), prior to the termination of the offering under this prospectus supplement:

- (a) Our Current Reports on Form 8-K filed on April 9, 2010 and May 24, 2010;
- (b) Our Quarterly Reports on Form 10-Q for the quarters ended March 31, 2010 and June 30, 2010; and
- (c) Our 2009 Annual Report on Form 10-K for the year ended December 31, 2009, including our 2009 Annual Report.

You may request a free copy of these filings by writing or telephoning the office of the Corporate Secretary, Aetna Inc., 151 Farmington Avenue, RW61, Hartford, Connecticut 06156, Telephone: (860) 273-4970.

**Table of Contents****CAPITALIZATION**

The following table shows our capitalization on a consolidated basis as of June 30, 2010 (unaudited) and as adjusted for the sale of \$750,000,000 aggregate principal amount of Notes offered by this prospectus supplement.

	<b>Actual</b>	<b>As Adjusted</b>
	<b>(Millions)</b>	
Short-term debt:		
Commercial paper program(1)	\$ 450.0	\$ 450.0
Total short-term debt	\$ 450.0	\$ 450.0
Long term debt:		
Senior notes, 5.75% due 2011	\$ 449.9	\$ 449.9
Senior notes, 7.875% due 2011	449.8	449.8
Senior notes, 6.0% due 2016	747.4	747.4
Senior notes, 6.5% due 2018	498.8	498.8
Senior notes, 6.625% due 2036	798.6	798.6
Senior notes, 6.75% due 2037	695.7	695.7
Senior notes, 3.95% due 2020		741.4
Total long term debt	\$ 3,640.2	\$ 4,381.6
Shareholders' Equity:		
Common stock and additional paid-in capital (\$.01 par value; 2.7 billion shares authorized, 417.4 million shares issued and outstanding)	\$ 542.4	\$ 542.4
Retained earnings	10,829.5	10,829.5
Accumulated other comprehensive loss	(1,025.6)	(1,025.6)
Total shareholders' equity	10,346.3	10,346.3
Total Capitalization	\$ 14,436.5	\$ 15,177.9

(1) At August 23, 2010, we had approximately \$697 million of commercial paper outstanding.

**Table of Contents**

**USE OF PROCEEDS**

Our net proceeds from this offering are estimated to be approximately \$735,767,500 after deducting underwriting discounts and estimated offering expenses. We will use these net proceeds for general corporate purposes, including the repayment of our short-term or long-term debt. Certain of the underwriters participating in this offering are dealers in our commercial paper program. To the extent that we use the proceeds of this offering to repay our short-term debt or long-term debt, including outstanding commercial paper borrowings, certain of those underwriters or their affiliates may receive proceeds from this offering as a result of their ownership of such debt. See Underwriting .

S-6

---

**Table of Contents****SELECTED FINANCIAL INFORMATION**

The following table sets forth our selected consolidated financial data for the five years ended December 31, 2009 and the six-month periods ended June 30, 2010 and June 30, 2009. The financial data for the six-month periods ended June 30, 2010 and June 30, 2009 is derived from our unaudited financial statements. The unaudited financial statements reflect all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of our financial position and results of operations during that period and as of that date. Operating results for the six months ended June 30, 2010 are not necessarily indicative of those to be expected for the full fiscal year.

The following information should be read in conjunction with Management's Discussion and Analysis of Financial Condition and Results of Operations and our consolidated financial statements and related notes included in our Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2010 and our 2009 Annual Report, each filed with the SEC and incorporated by reference in this prospectus supplement. See Where You Can Find More Information in this prospectus supplement.

	Six Months Ended		2009	Years Ended December 31,			2005 <sup>(1)</sup>
	2010	2009		2008	2007	2006	
				(Millions)			
<b>INCOME STATEMENT DATA:</b>							
Total revenue	\$ 17,167.3	\$ 17,285.5	\$ 34,764.1	\$ 30,950.7	\$ 27,599.6	\$ 25,145.7	\$ 22,491.9
Health care costs	11,349.6	11,906.6	24,061.2	20,785.5	17,294.8	15,301.0	13,107.9
Current and future benefits	1,007.7	1,007.1	2,078.1	1,938.7	2,248.1	2,319.0	2,364.5
Operating expenses	3,075.3	3,016.3	6,383.0	5,751.5	5,046.4	4,820.6	4,452.7
Interest expense	121.6	122.2	243.4	236.4	180.6	148.3	122.8
Amortization of other acquired intangible assets	48.6	49.0	97.2	108.2	97.6	85.6	57.4
Reduction of reserve for anticipated future losses on discontinued products				(43.8)	(64.3)	(115.4)	(66.7)
Total benefits and expenses	15,602.8	16,101.2	32,862.9	28,776.5	24,803.2	22,559.1	20,038.6
Income from continuing operations before income taxes	1,564.5	1,184.3	1,901.2	2,174.2	2,796.4	2,586.6	2,453.3

Edgar Filing: AETNA INC /PA/ - Form 424B5

Income taxes	510.9	399.9	624.7	790.1	965.4	901.0	880.0
Income from continuing operations	\$ 1,053.6	\$ 784.4	\$ 1,276.5	\$ 1,384.1	\$ 1,831.0	\$ 1,685.6	\$ 1,573.3
<b>BALANCE SHEET DATA (AT PERIOD END):</b>							
Total assets	\$ 38,347.8	\$ 36,762.6	\$ 38,550.4	\$ 35,852.5	\$ 50,724.7	\$ 47,626.4	\$ 44,433.3
Debt:							
Short-term	\$ 450.0	\$ 194.7	\$ 480.8	\$ 215.7	\$ 130.7	\$ 45.0	\$
Long-term	3,640.2	3,638.9	3,639.5	3,638.3	3,138.5	2,442.3	1,605.7
Total debt	\$ 4,090.2	\$ 3,833.6	\$ 4,120.3	\$ 3,854.0	\$ 3,269.2	\$ 2,487.3	\$ 1,605.7
Shareholders equity	\$ 10,346.3	\$ 8,877.2	\$ 9,503.8	\$ 8,186.4	\$ 10,038.4	\$ 9,145.1	\$ 10,188.7

(1) Effective January 1, 2006, we adopted new accounting guidance issued by the Financial Accounting Standards Board for stock based compensation applying the modified-retrospective approach. Accordingly, all prior period financial information was adjusted to reflect our stock-based compensation activity since 1995.

**Table of Contents**

**DESCRIPTION OF THE NOTES**

The Notes offered by this prospectus supplement are a series of senior debt securities as described in the accompanying prospectus. This description supplements the description of the general terms and provisions of the debt securities found in the accompanying prospectus.

Capitalized terms used and not otherwise defined below or elsewhere in this prospectus supplement or the accompanying prospectus are used with the respective meanings given thereto in the Senior Indenture dated as of March 2, 2001 between Aetna Inc. and U.S. Bank National Association, successor in interest to State Street Bank and Trust Company (the Senior Indenture). Any reference to the Notes contained in this prospectus supplement refers to the 3.95% Senior Notes due 2020 (the Notes) unless the context indicates otherwise.

The Senior Indenture does not restrict our ability to incur additional indebtedness, other than certain indebtedness secured by liens on common stock of our Principal Subsidiaries (as defined in the Senior Indenture). In addition to the limitation on liens, the Senior Indenture also contains a limitation on our ability to consolidate or merge with another person or sell our assets; however, these negative covenants contain important exceptions. See Description of Debt Securities Limitations on Liens on Common Stock of Principal Subsidiaries and Consolidation, Merger and Sale of Assets in the accompanying prospectus.

**General**

The Notes initially will be limited to \$750,000,000 aggregate principal amount. We may, without the consent of the holders of the Notes, increase such principal amounts in the future, on the same terms and conditions (except that the issue price and the issue date may vary) and with the same CUSIP number as the Notes being offered by this prospectus supplement. The Notes will be our senior unsecured general obligations and rank on a parity with all of our existing and future unsecured and unsubordinated indebtedness.

Principal of, and premium, if any, and interest on the Notes will be payable, and transfers of the Notes will be registrable, at our office or agency in the Borough of Manhattan, The City of New York. Transfers of the Notes will also be registrable at any of the other offices or agencies that we may maintain for that purpose. In addition, payment of interest may be made, at our option, by check mailed to the address of the person entitled thereto as shown on the security register. The Notes are to be in denominations of \$2,000 or any multiple of \$1,000 in excess thereof. No service charge will be made for any registration of transfer or exchange of Notes, except for any tax or other governmental charge that may be imposed in connection therewith.

**Interest; Maturity; No Sinking Fund**

Each Note will bear interest from August 27, 2010, payable semi-annually on March 1 and September 1 of each year, commencing March 1, 2011, to the person in whose name the Note is registered, subject to certain exceptions as provided in the Senior Indenture, at the close of business on February 15 or August 15, as the case may be, immediately preceding such March 1 or September 1. The Notes will bear interest at a rate of 3.95% per year. The Notes will mature on September 1, 2020. The Notes are not subject to any sinking fund provision. Interest on the Notes will be computed on the basis of a 360-day year comprised of twelve 30-day months. In any case where any interest payment date is not a Business Day (as defined in the Senior Indenture), then payment of interest may be made on the next succeeding Business Day without any additional amount being payable in respect of any delay.

**Optional Redemption**

The Notes will be redeemable at any time, in whole or in part, at a redemption price equal to the greater of:

100% of the principal amount of the Notes being redeemed, or

the sum of the present values of the remaining scheduled payments of principal and interest on the Notes being redeemed from the redemption date to the maturity date discounted to the redemption date

S-8

---

**Table of Contents**

on a semiannual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate (as defined below) plus 25 basis points,

plus, in each case, any interest accrued but not paid to the date of redemption.

The Treasury Rate means, with respect to any redemption date for any portion of the Notes,

the yield, under the heading which represents the average for the immediately preceding week, appearing in the most recently published statistical release designated H.15(519) or any successor publication which is published weekly by the Board of Governors of the Federal Reserve System and which establishes yields on actively traded United States Treasury securities adjusted to constant maturity under the caption Treasury Constant Maturities, for the maturity corresponding to the Comparable Treasury Issue (if no maturity is within three months before or after the maturity date for the Notes, yields for the two published maturities most closely corresponding to the Comparable Treasury Issue will be determined and the Treasury Rate shall be interpolated or extrapolated from those yields on a straight line basis, rounding to the nearest month), or

if the release referred to in the previous bullet (or any successor release) is not published during the week preceding the calculation date or does not contain the yields referred to above, the rate per annum equal to the semi-annual equivalent yield to maturity of the Comparable Treasury Issue, calculated using a price for the Comparable Treasury Issue (expressed as a percentage of its principal amount) equal to the Comparable Treasury Price for that redemption date.

The Treasury Rate will be calculated on the third Business Day preceding the redemption date.

*Comparable Treasury Issue* means the United States Treasury security selected by an Independent Investment Banker as having a maturity comparable to the remaining term of the Notes to be redeemed that would be utilized, at the time of selection and in accordance with customary financial practice, in pricing new issues of corporate debt securities of comparable maturity to the remaining term of the Notes to be redeemed.

*Comparable Treasury Price* means, with respect to any redemption date for any Notes, the average of all Reference Treasury Dealer Quotations (as defined below) obtained.

*Independent Investment Banker* means one of the Reference Treasury Dealers appointed by the Trustee after consultation with us.

*Reference Treasury Dealer* means each of Barclays Capital Inc., RBS Securities Inc. and UBS Securities LLC. If any Reference Treasury Dealer ceases to be a primary U.S. government securities dealer in the United States (a Primary Treasury Dealer), we will substitute another Primary Treasury Dealer for that dealer.

*Reference Treasury Dealer Quotations* means, with respect to each Reference Treasury Dealer and any redemption date, the average, as determined by the Trustee, of the bid and asked prices for the Comparable Treasury Issue (expressed in each case as a percentage of its principal amount) quoted in writing to the Trustee by that Reference Treasury Dealer at 5:00 p.m. on the third Business Day preceding the redemption date.

Notice of any redemption will be mailed at least 30 days but no more than 60 days before the redemption date to each holder of Notes to be redeemed.

Unless we default in payment of the redemption price, interest will cease to accrue on the Notes or portions of the Notes called for redemption on and after the redemption date.



**Repurchase Upon a Change of Control**

If a Change of Control Triggering Event occurs, unless we have exercised our right to redeem the Notes in full, as described under "Optional Redemption" above, we will make an offer to each holder (the "Change of Control Offer") to repurchase any and all (equal to \$2,000 or an integral multiple of \$1,000) of such holder's Notes at a repurchase price in cash equal to 101% of the aggregate principal amount of the Notes

S-9

---

**Table of ContentsFinancial and Accounting Officer)**

\*

Chairman of the Board of Directors

Thomas D. Champion

\*

Director

William M. Barnum, Jr.

\*

Director

David DeMattei

\*

Director

Matthew L. Hyde

\*

Director

James M. Weber

\*

Director

Gerald F. Ryles

---

\* */s/ Richard M. Brooks*  
Richard M. Brooks

Attorney-in-fact

II-5

---

**INDEX TO EXHIBITS**

<b>Exhibit Number</b>	<b>Description</b>
4.1	Form of Common Stock Certificate of Zumiez Inc. [Incorporated by reference to Exhibit 4.1 to the Company's Registration Statement on Form S-1 (File No. 333-122865)]
5.1*	Opinion of Kirkpatrick & Lockhart Preston Gates Ellis LLP
23.1	Consent of Moss Adams, LLP, Independent Registered Public Accounting Firm
23.2	Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm
23.3*	Consent of Kirkpatrick & Lockhart Preston Gates Ellis LLP (included in Exhibit 5.1)
24.1*	Power of Attorney (included as part of the signature page to this Registration Statement)

---

\* Previously filed.

II-6

---